levonorgestrel 1.5mg tablets
lupin healthcare (uk) ltd - levonorgestrel - oral tablet - 1.5mg
levonorgestrel tablet
novel laboratories, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 1.5 mg - levonorgestrel tablet, 1.5 mg is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. to obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse. levonorgestrel tablet is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. levonorgestrel tablet is not indicated for routine use as a contraceptive. levonorgestrel tablet is contraindicated for use in the case of known or suspected pregnancy. many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. the few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects. in general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the hea
levonorgestrel tablet
pharmacist pharmaceutical, llc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 1.5 mg - levonorgestrel tablet, 1.5 mg is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. to obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse. levonorgestrel tablet is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. levonorgestrel tablet is not indicated for routine use as a contraceptive. levonorgestrel tablet is contraindicated for use in the case of known or suspected pregnancy. many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. the few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects. in general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the hea
levonorgestrel and ethinyl estradiol and ethinyl estradiol- levonorgestrel and ethinyl estradiol and ethinyl estradiol
mayne pharma inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets is indicated for use by females of reproductive age to prevent pregnancy. do not prescribe levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)]. have cerebrovascular disease [see warnings and precautions (5.1)]. have coronary artery disease [see warnings and precautions (5.1)]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)]. have inherited or acquired h
levonorgestrel 1.5mg tablets
de pharmaceuticals - levonorgestrel - oral tablet - 1.5mg
levonorgestrel-1 gh levonorgestrel 1.5mg tablet blister pack
lupin australia pty limited - levonorgestrel, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; povidone; colloidal anhydrous silica - emergency contraception within 72 hours of unprotected intercourse.
levonorgestrel and ethinyl estradiol and ethinyl estradiol kit
mylan pharmaceuticals inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets are indicated for use by females of reproductive age to prevent pregnancy. levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: risk summary there is no use for contraception in pregnancy; therefore, levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to chcs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. risk summary contraceptive hormones and/or metabolites are present in human milk. chcs
levonorgestrel and ethinyl estradiol kit
glenmark pharmaceuticals inc., usa - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - levonorgestrel and ethinyl estradiol tablets are indicated for use by females of reproductive potential to prevent pregnancy. levonorgestrel and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: risk summary there is no use for contraception in pregnancy; therefore, levonorgestrel and ethinyl estradiol tablets should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to cocs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. risk summary contraceptive hormones and/or metabolites are present in human milk. cocs can reduce milk production in breastfeeding females. this reduction can occur at any
levonorgestrel 1.5mg tablets
consilient health ltd - levonorgestrel - oral tablet - 1.5mg
levonorgestrel 1.5mg tablets
alliance healthcare (distribution) ltd - levonorgestrel - oral tablet - 1.5mg